Inovio Pharmaceuticals (INO) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares.
View INO analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 12-month target prices for Inovio Pharmaceuticals' stock. Their INO share price forecasts range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 282.6% from the stock's current price.
View analysts price targets for INO or view top-rated stocks among Wall Street analysts.

Inovio Pharmaceuticals' stock was trading at $1.56 at the beginning of the year. Since then, INO stock has decreased by 66.5% and is now trading at $0.5228.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our INO earnings forecast.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) posted its quarterly earnings data on Wednesday, May, 10th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.02. The biopharmaceutical company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.20 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 97.93% and a negative net margin of 2,371.71%. During the same quarter in the prior year, the firm posted ($0.36) earnings per share.

ETFs with the largest weight of Inovio Pharmaceuticals (NASDAQ:INO) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), iShares Genomics Immunology and Healthcare ETF (IDNA), ETFMG Treatments Testing and Advancements ETF (GERM), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Biotech ETF (XBI) and WisdomTree BioRevolution Fund (WDNA).Direxion Daily S&P Biotech Bull 3x Shares (LABU).

Shares of Inovio Pharmaceuticals reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

12 employees have rated Inovio Pharmaceuticals Chief Executive Officer J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Inovio Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (10.62%), BlackRock Inc. (8.93%), Geode Capital Management LLC (1.97%), Bank of America Corp DE (1.35%), Renaissance Technologies LLC (1.01%) and Citigroup Inc. (0.72%). Insiders that own company stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends.

Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INO stock can currently be purchased for approximately $0.52.

Inovio Pharmaceuticals (NASDAQ:INO) has a market capitalization of $137.36 million and generates $10.26 million in revenue each year. The biopharmaceutical company earns $-279,820,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis.

The company employs 317 workers across the globe.

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The official website for the company is www.inovio.com. The biopharmaceutical company can be reached via phone at (267) 440-4200, via email at investor.relations@inovio.com, or via fax at 267-440-4242.